Cerapedics has been awarded a group purchasing agreement with Premier, a healthcare improvement company.
The new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for I-Factor peptide-enhanced bone graft. The contract is effective December 1, 2016.
“We are pleased to announce our new agreement with Premier because it will help us provide a growing number of surgeons with the advanced biologic they need to stimulate a natural bone healing process in patients with degenerative cervical disc disease,” says Glen Kashuba, chief executive officer of Cerapedics. “We look forward to the continued expansion of I-Factor bone graft commercialisation into the new year.”
I-Factor bone graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. Supported by Level I human clinical data, I-Factor bone graft received Premarket Approval (PMA) from the US Food and Drug Administration (FDA) in November 2015.
Premier’s alliance comprises approximately 3,750 US hospitals and 130,000 other provider organisations.